We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GRASSLEY THREATENS FDA WITH HEARINGS BASED ON KETEK INVESTIGATION

GRASSLEY THREATENS FDA WITH HEARINGS BASED ON KETEK INVESTIGATION

June 15, 2006

Rebuffed in his attempt to force a face-to-face meeting with an FDA special investigator, Sen. Chuck Grassley has charged the agency with covering up problems with its review of the antibiotic Ketek and threatened to hold hearings on the way regulators determine the safety of drugs.

The Iowa Republican made a personal visit to the source of his displeasure, arriving at HHS headquarters in Washington a day after he sent the agency a letter demanding that the FDA provide him with information he has been seeking on the approval of sanofi-aventis' Ketek (telithromycin) and arrange a meeting with an agency special investigator.

Grassley, the chairman of the Senate Finance Committee, has been asking the agency since April for information about fraud that allegedly compromised a study on the safety of Ketek, but has yet to receive answers to his questions. The final straw came when the FDA denied Grassley's request to meet with the agency investigator in charge of the Ketek review.

Grassley contends that the FDA's handling of Ketek is indicative of flaws in the agency's overall drug review system. This situation "falls into the pattern" of FDA missteps in dealing with drug safety, Grassley said.

Grassley did meet with several high-ranking agency officials on June 14, including Vince Ventimiglia, HHS assistant secretary for legislation, and Casey Hemard, the agency's counselor on oversight to the assistant secretary for legislation. He also met with David Boyer, FDA assistant commissioner for legislation, and Horace Coleman, special agent in charge in the agency's Office of Criminal Investigations. But these officials refused to provide Grassley with access to the agent in charge of the Ketek investigation.

"I smell a cover-up," Grassley said of the agency's refusal to grant his request. Addressing the agency, Grassley said "it's probably not your intent to cover for companies, but every time you stand in the way of information getting out that ought to be public that's the impression you give the American people." Also, internal emails that he has obtained show the agency has a "cozy relationship" with industry, he added. (http://www.fdanews.com/did/5_117/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing